$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

$shph Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223028462 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$458.8K	$532.3K	$269.8K
YoY Change	201.02%	97.31%	439.52%
% of Gross Profit
Research & Development	$1.140M	$933.4K	$83.87K
YoY Change	70.44%	1012.88%	-71.08%
% of Gross Profit
Depreciation & Amortization	$4.830K	$1.480K	$1.450K
YoY Change	205.7%	2.07%
% of Gross Profit
Operating Expenses	$1.599M	$1.466M	$353.6K
YoY Change	94.67%	314.45%	4.01%
Operating Profit	-$1.599M	-$1.466M	-$353.6K
YoY Change	94.67%	314.46%
Interest Expense	-$150.2K	-$303.2K	-$243.7K
YoY Change	-70.3%	24.44%	2336.5%
% of Operating Profit
Other Income/Expense, Net	-$193.6K	-$718.7K	-$243.6K
YoY Change	9.41%	194.99%
Pretax Income	-$1.775M	-$2.184M	-$597.3K
YoY Change	77.81%	265.72%	70.65%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.793M	-$2.184M	-$597.3K
YoY Change	79.56%	265.72%	72.22%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.11	-$0.15	-$0.06
Diluted Earnings Per Share	-$0.11	-$0.15	-$0.05
COMMON SHARES
Basic Shares Outstanding	15.73M shares	13.80M shares	9.313M shares
Diluted Shares Outstanding	1.970M shares	14.26M shares	9.313M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.807M	$8.350M	$50.44K
YoY Change	-25.37%	16454.32%
Cash & Equivalents	$3.886M	$5.447M	$50.44K
Short-Term Investments	$2.921M	$2.900M
Other Short-Term Assets	$6.480K	$6.480K	$13.52K
YoY Change	-96.03%	-52.07%
Inventory
Prepaid Expenses	$170.1K	$78.95K
Receivables	$12.44K	$10.00K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$6.996M	$8.443M	$63.95K
YoY Change	-24.69%	13103.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.81K	$9.622K	$103.1K
YoY Change	90.41%	-90.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$6.480K
YoY Change		-100.0%
Total Long-Term Assets	$380.2K	$393.8K	$109.5K
YoY Change	310.9%	259.5%
TOTAL ASSETS
Total Short-Term Assets	$6.996M	$8.443M	$63.95K
Total Long-Term Assets	$380.2K	$393.8K	$109.5K
Total Assets	$7.376M	$8.837M	$173.5K
YoY Change	-21.38%	4994.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$180.0K	$90.00K	$515.8K
YoY Change	67.99%	-82.55%
Accrued Expenses	$167.6K	$140.0K	$181.7K
YoY Change	-5.75%	-22.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$1.261M
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$462.8K	$270.0K	$0.00
YoY Change
Total Short-Term Liabilities	$810.4K	$493.7K	$2.454M
YoY Change	-16.49%	-79.88%
LONG-TERM LIABILITIES
Long-Term Debt	$134.4K	$120.0K	$0.00
YoY Change
Other Long-Term Liabilities	$821.3K	$1.290M	$25.60K
YoY Change	12212.59%	4939.06%
Total Long-Term Liabilities	$955.6K	$1.410M	$25.60K
YoY Change	14227.29%	5407.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$810.4K	$493.7K	$2.454M
Total Long-Term Liabilities	$955.6K	$1.410M	$25.60K
Total Liabilities	$1.766M	$1.901M	$2.480M
YoY Change	80.74%	-23.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$13.85M	-$12.05M
YoY Change	70.03%
Common Stock	$160.00	$155.00
YoY Change	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.610M	$6.936M	-$2.306M
YoY Change
Total Liabilities & Shareholders Equity	$7.376M	$8.837M	$173.5K
YoY Change	-21.38%	4994.02%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$1.793M	-$2.184M	-$597.3K
YoY Change	79.56%	265.72%	72.22%
Depreciation, Depletion And Amortization	$4.830K	$1.480K	$1.450K
YoY Change	205.7%	2.07%
Cash From Operating Activities	-$1.539M	-$1.646M	-$355.4K
YoY Change	46.49%	363.13%	788.55%
INVESTING ACTIVITIES
Capital Expenditures	$19.05K		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$7.710K	$62.80K
YoY Change
Cash From Investing Activities	-$26.76K	$62.80K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.530K	-139.2K	0.000
YoY Change	-99.96%
NET CHANGE
Cash From Operating Activities	-1.539M	-1.646M	-355.4K
Cash From Investing Activities	-26.76K	62.80K	0.000
Cash From Financing Activities	4.530K	-139.2K	0.000
Net Change In Cash	-1.561M	-1.722M	-355.4K
YoY Change	-117.21%	384.64%	788.55%
FREE CASH FLOW
Cash From Operating Activities	-$1.539M	-$1.646M	-$355.4K
Capital Expenditures	$19.05K		$0.00
Free Cash Flow	-$1.558M		-$355.4K
YoY Change	48.3%		788.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001757499
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q2	us-gaap	Other Assets OtherAssets		usd
CY2022Q4	SHPH	Convertible Note Payable Current ConvertibleNotePayableCurrent		usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
	SHPH	Finance Fee FinanceFee		usd
CY2022Q2	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
CY2022Q2	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments		usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments		usd
CY2022Q2	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt		usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt		usd
CY2023Q2	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
CY2022Q2	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
CY2023Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments		usd
	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock		usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt		usd
	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet		usd
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	SHPH	Common Stock Issued For Conversion Of Accrued Interest CommonStockIssuedForConversionOfAccruedInterest		usd
	SHPH	Common Stock Issued For Settlement Of Debt And Interest CommonStockIssuedForSettlementOfDebtAndInterest		usd
	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees		usd
	SHPH	Initial Recognition Of Right Of Use Asset And Liability InitialRecognitionOfRightOfUseAssetAndLiability		usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	955725	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	329774	usd
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41488
	dei	Entity Registrant Name EntityRegistrantName	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5089826
	dei	Entity Address Address Line1 EntityAddressAddressLine1	401 Professional Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 260
	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20879
	dei	City Area Code CityAreaCode	(240)
	dei	Local Phone Number LocalPhoneNumber	403-4212
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	SHPH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15733165	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5446786	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8417203	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	78949	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	161148	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2904177	usd
CY2023Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	6950	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	6480	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	8443342	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8578351	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9622	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12592	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	6480	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	384137	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	56122	usd
CY2023Q2	us-gaap	Assets Assets	8837101	usd
CY2022Q4	us-gaap	Assets Assets	8653545	usd
CY2023Q2	SHPH	Convertible Note Payable Current ConvertibleNotePayableCurrent	268396	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	61034	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	62823	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	493682	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	975676	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	122309	usd
CY2023Q2	us-gaap	Liabilities Liabilities	1901490	usd
CY2022Q4	us-gaap	Liabilities Liabilities	975676	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q2	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15482038	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15482038	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13603129	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13603129	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	155	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	136	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18989813	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16572622	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12054357	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8894889	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6935611	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8837101	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8653545	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	933373	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	83868	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1944181	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	379783	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	115571	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9078	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	281918	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22847	usd
CY2023Q2	us-gaap	Legal Fees LegalFees	416688	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	260680	usd
	us-gaap	Legal Fees LegalFees	784312	usd
	us-gaap	Legal Fees LegalFees	589392	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1465632	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	353626	usd
	us-gaap	Operating Expenses OperatingExpenses	3010411	usd
	us-gaap	Operating Expenses OperatingExpenses	992022	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1465632	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-353626	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3010411	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-992022	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	19267	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	35955	usd
	SHPH	Finance Fee FinanceFee	104245	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	434275	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-58422	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1675275	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-18772	usd
CY2023Q2	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	1744	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	1744	usd
CY2023Q2	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-26534	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	11528	usd
CY2023Q2	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	415553	usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	433807	usd
	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable	73007	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-718740	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-243649	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-149057	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-287092	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2184372	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-597275	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3159468	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1279114	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	25768	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	51536	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2184372	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-623043	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3159468	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1330650	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14261313	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14261313	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9312991	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9312991	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13950355	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13950355	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9291526	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9291526	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14261313	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9312991	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13950355	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9291526	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	99543	usd
CY2023Q1	SHPH	Financing Fees Allocated To Warrants FinancingFeesAllocatedToWarrants	-8727	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	104547	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8333	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-975097	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6906468	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6906468	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2163992	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49522	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2184372	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6935611	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6935611	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1628132	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	319643	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	166533	usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	25768	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-681839	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1849563	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1849563	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	166533	usd
CY2022Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	25768	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-597275	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2306073	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2306073	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3159468	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1279114	usd
	us-gaap	Depreciation Depreciation	2970	usd
	us-gaap	Depreciation Depreciation	2899	usd
	SHPH	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1675275	usd
	SHPH	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-18772	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1116422	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	278531	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	1744	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	11528	usd
	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock	240831	usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	433807	usd
	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable	73007	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	57855	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	333066	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	6950	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-82199	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	8649	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-28004	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-312527	usd
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-12500	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	75511	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	37276	usd
	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	-98135	usd
	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	25383	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-30	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2657	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2984039	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-980027	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2970905	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	80000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2890905	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-685473	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3935000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	525715	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	345000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2904527	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	525715	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2970417	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-454312	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8417203	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	504749	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5446786	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50437	usd
	us-gaap	Interest Paid Net InterestPaidNet	102373	usd
	SHPH	Common Stock Issued For Conversion Of Accrued Interest CommonStockIssuedForConversionOfAccruedInterest	16340	usd
	SHPH	Common Stock Issued For Settlement Of Debt And Interest CommonStockIssuedForSettlementOfDebtAndInterest	2268539	usd
	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees	90816	usd
	SHPH	Initial Recognition Of Right Of Use Asset And Liability InitialRecognitionOfRightOfUseAssetAndLiability	365556	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3159468	usd
CY2022Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	10022193	usd
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	5195000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zRY1rxzxYfU7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zYBmId898Rm3">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zMOpI0aDDOXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zLvHXkZaT737">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the accompanying financial statements for the valuation of derivatives, the valuation allowance on deferred tax assets, share-based compensation, useful lives for depreciation and amortization of long-lived assets, and the incremental borrowing rate used on right-of-use assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Cash Cash	4435870	usd
CY2022Q4	us-gaap	Cash Cash	5411378	usd
CY2023Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1010916	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	3005825	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5446786	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8417203	usd
CY2023Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2904177	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	35955	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	1744	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	11528	usd
CY2023Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	955725	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2772226	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	145593	shares
	us-gaap	Lessee Operating Lease Assumptions And Judgments Discount Rate Description LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription	The interest rate used to determine the present value of our lease ending in October of 2023 was our incremental borrowing rate estimated at 10% when the lease was entered into in 2019. Our new lease beginning in June of 2023, the interest rate used was an equity built up, risk adjusted rate, estimated to be 10.48%, as the interest rate implicit in most of our leases is not readily determinable
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The first is for a monthly payment of $6,480, with a security deposit of $6,480 held for the duration of the lease, and commenced on October 1, 2018, with the first payment made on January 1, 2019
	us-gaap	Payments For Rent PaymentsForRent	6480	usd
CY2023Q2	us-gaap	Deposits Deposits	6480	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-10-31
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	43234	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	3891	usd
	SHPH	Cam Cost CamCost	3315	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	42737	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	35088	usd
	us-gaap	Sublease Income SubleaseIncome	4242	usd
	us-gaap	Sublease Income SubleaseIncome	2121	usd
	us-gaap	Lease Cost LeaseCost	38495	usd
	us-gaap	Lease Cost LeaseCost	32967	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	42771	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	37746	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	365556	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y11M23D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M18D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1046	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2021Q4	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	In December of 2021 the maturity dates of these loans were further extended to June 30, 2022. In July of 2022, the notes were extended to June 30, 2023
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	10000000	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	549125	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1012177	usd
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	2921100	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2530394	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	390706	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1827911	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	839	shares
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	839	shares
CY2022Q2	SHPH	Accrued Interest Value To Issue Shares AccruedInterestValueToIssueShares	16340	usd
	SHPH	Accrued Interest Value To Issue Shares AccruedInterestValueToIssueShares	16340	usd
CY2022Q2	SHPH	Common Stock Vesting Of Restricted Stock Unit CommonStockVestingOfRestrictedStockUnit	5104	shares
	SHPH	Common Stock Vesting Of Restricted Stock Unit CommonStockVestingOfRestrictedStockUnit	10208	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1018079	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.35
CY2023Q2	SHPH	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	399905	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1018079	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.35
CY2023Q1	SHPH	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Value ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue	1189000	usd
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	2631000	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	955725	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-028462-index-headers.html	Edgar Link	pending
0001493152-23-028462-index.html	Edgar Link	pending
0001493152-23-028462.txt	Edgar Link	pending
0001493152-23-028462-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
shph-20230630.xsd	Edgar Link	pending
shph-20230630_cal.xml	Edgar Link	unprocessable
shph-20230630_def.xml	Edgar Link	unprocessable
shph-20230630_pre.xml	Edgar Link	unprocessable
shph-20230630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2023 Q3 Form 10-Q Financial Statement

#000149315223028462 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2023 Q3 Form 10-Q Financial Statement

#000149315223028462 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph